93 results
8-K
EX-99.1
PLSE
Pulse Biosciences, Inc.
8 Aug 24
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
9:09am
. “We are excited to continue enrollment in this feasibility clinical study, which is intended to demonstrate the device’s safety, effectiveness … and whether they are predictive of the safety and efficacy of any medical device such as the CellFX nsPFA Cardiac Surgery System, and Pulse Biosciences
424B5
PLSE
Pulse Biosciences, Inc.
15 Jul 24
Prospectus supplement for primary offering
7:04am
protocol to treat up to 30 patients in the Netherlands. This study would provide information on first-in-human effectiveness and safety with our cardiac … meet the FDA’s rigorous standards for device safety and effectiveness in order to be authorized for marketing.
CellFX nsPFA 360° Cardiac Catheter
We
8-K
EX-99.1
PLSE
Pulse Biosciences, Inc.
8 Jul 24
Other Events
4:13pm
for device safety and effectiveness in order to be authorized for marketing.
“The Breakthrough Device Designation granted by the FDA is an exciting … to address a range of conditions such as atrial fibrillation, statements concerning early clinical successes and whether they are predictive of the safety
424B2
PLSE
Pulse Biosciences, Inc.
4 Jun 24
Prospectus for primary offering
4:05pm
evaluating the safety and efficacy of the Company’s CellFX nsPFA Cardiac Clamp and CellFX nsPFA 360° Cardiac Catheter for the treatment of atrial … ongoing investment in current and future clinical studies evaluating the safety and efficacy of the Company’s CellFX nsPFA Cardiac Clamp and CellFX
POS AM
p50xke38v zoml5qn3v
28 May 24
Prospectus update (post-effective amendment)
5:19pm
8-K
EX-99.1
frs7wsyc0w9
20 May 24
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
4:10pm
8-K
EX-99.1
zq47gtx9cglhsbmvwe
15 May 24
Pulse Biosciences Enhances Executive Leadership Team
9:05am
8-K
EX-99.1
2tcd597haf4blc7ddev
9 May 24
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
9:09am
8-K
EX-99.1
baw30 lam
7 May 24
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
4:14pm
8-K
EX-99.1
86mka97rj6pzxgls
28 Mar 24
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
tvdbfaitn
11 Mar 24
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
9:10am